The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Featured:
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Andrew Matthews, University of Pennsylvania, Philadelphia, US. We asked, What do real-world data tell us about outcomes with venetoclax/hypomethylating agents (HMA) vs 7+3 chemotherapy?
What do real-world data tell us about outcomes with venetoclax/HMA vs 7+3 chemotherapy?
Matthews discusses a national, multicenter, retrospective study comparing venetoclax/HMA and 7+3 chemotherapy in patients aged 60–75 years, newly diagnosed with AML, and without major heart failure or chronic kidney disease, spanning all risk groups and mutational profiles. Matthews outlines the differences in baseline characteristics between the two treatment groups and highlights that although adverse events were more common in patients who received intensive chemotherapy, overall survival was significantly longer compared with those who received venetoclax/HMA.